Phase 3 study for people with COPD

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor AstraZeneca
Registry number NCT06878261
Started 25 March 2025 Today 16 October 2026 Estimated completion 13 March 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Research Site Coffs Harbour Australia Recruiting
Research Site Frankston VIC Recruiting
Research Site Garran ACT Withdrawn
Research Site Nedlands WA Recruiting
Research Site New Lambton NSW Completed
Research Site Spearwood WA Recruiting
Research Site Wollongong NSW Withdrawn
Research Site Woodville South SA Completed

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 40 Years to 80 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 990

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. ≥40 to ≤80 years old

2. COPD diagnosis ≥1 year,

3. Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC \<0.70 at screening

4. Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1

5. ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy

6. EOS ≥ 150 cells/μL during screening

7. CAT ≥15 at screening

8. Former or current smokers ≥10 pack-years

Exclusion Criteria:

1. Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD

2. Asthma, incl. pediatric, or ACOS

3. Any unstable disorder that can impact participants safety or study outcomes

4. Tuberculosis requiring treatment within 12 months prior V2

5. Malignancies current or past

Concomitant therapies:

* Macrolides (less than 6 months)

* Systemic immuno-suppressive, -modulating medications

6. LTOT \>4.0 L/min or O2 saturation \<89% despite LTOT

Dates on the record

Started 25 March 2025
Estimated completion 13 March 2029
Registry last updated 9 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 9 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.